[go: up one dir, main page]

PA8776601A1 - Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1- oxido-piridin-4-il)-5(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal - Google Patents

Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1- oxido-piridin-4-il)-5(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal

Info

Publication number
PA8776601A1
PA8776601A1 PA20088776601A PA8776601A PA8776601A1 PA 8776601 A1 PA8776601 A1 PA 8776601A1 PA 20088776601 A PA20088776601 A PA 20088776601A PA 8776601 A PA8776601 A PA 8776601A PA 8776601 A1 PA8776601 A1 PA 8776601A1
Authority
PA
Panama
Prior art keywords
piridin
medula
metoxi
dicloro
oxido
Prior art date
Application number
PA20088776601A
Other languages
English (en)
Inventor
Delay-Goyet Philippe
Ferzaz Badia
Lolivier Jocelyne
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8776601A1 publication Critical patent/PA8776601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE 4-CICLOPROPILMETOXI-N-(3,5-DICLORO-1-OXIDO-PIRIDIN-4-IL)-5-(METOXI) PIRIDIN-2 CARBOXAMIDA PARA LA PREPARACION DE UN MEDICAMENTO DESTINADO AL TRATAMIENTO DE LOS TRAUMATISMO DE MEDULA ESPINAL.
PA20088776601A 2007-04-19 2008-04-15 Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1- oxido-piridin-4-il)-5(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal PA8776601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702851A FR2915098B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Publications (1)

Publication Number Publication Date
PA8776601A1 true PA8776601A1 (es) 2008-11-19

Family

ID=38779706

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088776601A PA8776601A1 (es) 2007-04-19 2008-04-15 Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1- oxido-piridin-4-il)-5(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal

Country Status (32)

Country Link
US (1) US8592443B2 (es)
EP (1) EP2150253B1 (es)
JP (1) JP5386477B2 (es)
KR (1) KR101470043B1 (es)
CN (1) CN101674829B (es)
AR (1) AR066106A1 (es)
AT (1) ATE503481T1 (es)
AU (1) AU2008257321B2 (es)
BR (1) BRPI0810446A2 (es)
CA (1) CA2684172C (es)
CL (1) CL2008001134A1 (es)
CY (1) CY1111779T1 (es)
DE (1) DE602008005873D1 (es)
DK (1) DK2150253T3 (es)
EA (1) EA015355B1 (es)
ES (1) ES2363056T3 (es)
FR (1) FR2915098B1 (es)
HR (1) HRP20110459T1 (es)
IL (1) IL201451A (es)
JO (1) JO2662B1 (es)
MA (1) MA31369B1 (es)
ME (1) ME00934B (es)
MX (1) MX2009011285A (es)
MY (1) MY146657A (es)
NZ (1) NZ580483A (es)
PA (1) PA8776601A1 (es)
PL (1) PL2150253T3 (es)
PT (1) PT2150253E (es)
SI (1) SI2150253T1 (es)
TW (1) TWI411435B (es)
UY (1) UY31033A1 (es)
WO (1) WO2008145840A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2915099B1 (fr) 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
CA2892151A1 (en) * 2012-11-28 2014-06-05 Sanofi Process for preparing 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide
WO2014083107A1 (en) * 2012-11-28 2014-06-05 Sanofi METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
WO2022159632A1 (en) 2021-01-20 2022-07-28 Alto Neuroscience, Inc. Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
WO1995004045A1 (en) * 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
US6196968B1 (en) 1997-06-02 2001-03-06 General Surgical Innovations, Inc. Direct vision subcutaneous tissue retractor and method for use
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
JP2003519139A (ja) * 1999-12-23 2003-06-17 アイコス コーポレイション 環状ａｍｐ−特異的ホスホジエステラーゼ阻害剤
CA2439691A1 (en) 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2005538972A (ja) 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンｐｄｅ４阻害剤
WO2004067006A1 (en) 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US7338950B2 (en) * 2003-10-07 2008-03-04 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
JP2008543781A (ja) * 2005-06-10 2008-12-04 メモリー・ファーマシューティカルズ・コーポレイション ホスフオジエステラーゼ４阻害剤
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
DE602008005873D1 (de) 2011-05-12
JP2010524905A (ja) 2010-07-22
JO2662B1 (en) 2012-06-17
WO2008145840A2 (fr) 2008-12-04
CY1111779T1 (el) 2015-10-07
AU2008257321A1 (en) 2008-12-04
CL2008001134A1 (es) 2009-01-16
UY31033A1 (es) 2008-11-28
KR101470043B1 (ko) 2014-12-05
IL201451A (en) 2013-04-30
WO2008145840A3 (fr) 2009-06-25
SI2150253T1 (sl) 2011-07-29
US20100137370A1 (en) 2010-06-03
ES2363056T3 (es) 2011-07-19
IL201451A0 (en) 2010-05-31
DK2150253T3 (da) 2011-07-25
JP5386477B2 (ja) 2014-01-15
ATE503481T1 (de) 2011-04-15
EA015355B1 (ru) 2011-06-30
EP2150253A2 (fr) 2010-02-10
PT2150253E (pt) 2011-06-17
CA2684172A1 (fr) 2008-12-04
MA31369B1 (fr) 2010-05-03
US8592443B2 (en) 2013-11-26
CN101674829A (zh) 2010-03-17
ME00934B (me) 2012-06-20
EP2150253B1 (fr) 2011-03-30
KR20090130063A (ko) 2009-12-17
EA200970969A1 (ru) 2010-02-26
PL2150253T3 (pl) 2011-08-31
AU2008257321B2 (en) 2013-08-15
BRPI0810446A2 (pt) 2014-10-14
FR2915098B1 (fr) 2009-06-05
FR2915098A1 (fr) 2008-10-24
MX2009011285A (es) 2009-11-02
NZ580483A (en) 2011-06-30
CN101674829B (zh) 2012-01-18
AR066106A1 (es) 2009-07-22
HRP20110459T1 (hr) 2011-07-31
CA2684172C (fr) 2015-10-27
MY146657A (en) 2012-09-14
TW200911248A (en) 2009-03-16
TWI411435B (zh) 2013-10-11
HK1142000A1 (en) 2010-11-26

Similar Documents

Publication Publication Date Title
CR7261A (es) Derivados de diarilcicloalquilo, procedimiento para su preparacion y su utilizacion como agentes activadores del ppar
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CR8858A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
ATE530524T1 (de) Substituierte sulfonamid-derivate
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
UY30282A1 (es) Compuestos quimicos
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
GT200600117A (es) Nuevos compuestos farmaceuticos
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
PA8776601A1 (es) Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1- oxido-piridin-4-il)-5(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal
CR8270A (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo